Format

Send to

Choose Destination
Clin Cancer Res. 2014 Nov 1;20(21):5547-57. doi: 10.1158/1078-0432.CCR-13-3483. Epub 2014 Apr 25.

Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.

Author information

1
Departments of Urology and Surgery, Royal Melbourne Hospital;
2
NICTA Victoria Research Laboratory, University of Melbourne, Parkville;
3
TissuPath Specialist Pathology, Mount Waverley; The Faculty of Medicine, Monash University, Melbourne; and.
4
Departments of Urology and Surgery, Royal Melbourne Hospital; Australian Prostate Cancer Research Centre Epworth, Richmond, Victoria, Australia.
5
Departments of Urology and Surgery, Royal Melbourne Hospital; Australian Prostate Cancer Research Centre Epworth, Richmond, Victoria, Australia niallmcorcoran@gmail.com.

Abstract

PURPOSE:

It has been recognized for almost a decade that concentrations of signaling androgens sufficient to activate the androgen receptor are present in castration-resistant prostate cancer tissue. The source of these androgens is highly controversial, with three competing models proposed. We, therefore, wished to determine the androgenic potential of human benign and malignant (hormone-naïve and treated) prostate tissue when incubated with various precursors and examine concomitant changes in enzyme expression.

EXPERIMENTAL DESIGN:

Freshly harvested prostate tissue [benign, hormone-naïve, and hormone-refractory prostate cancer (HRPC)] was incubated in excess concentrations of cholesterol, progesterone, DHEA, androstenedione, or testosterone for 96 hours, and steroid concentrations in the conditioned media measured by gas chromatography-mass spectroscopy. Changes in the expression of androgen synthetic and/or degradative enzymes were determined by expression microarray and qPCR. Significant changes were confirmed in an independent dataset.

RESULTS:

Of the precursor molecules tested, only incubation with androstenedione gave rise to significant concentrations of signaling androgens. Although this was observed in all tissue types, it occurred to a significantly greater degree in hormone-refractory compared with hormone-naïve cancer. Consistent with this, gene set enrichment analysis of the expression microarray data revealed significant upregulation of 17HSD17B activity, with overexpression of the canonical enzyme AKR1C3 confirmed by qPCR in the same samples and in a publicly available expression dataset. Importantly, we found no evidence to support a significant contribution from either the "backdoor" or "5-α dione" pathway.

CONCLUSIONS:

Reduction of androstenedione to testosterone by the canonical HSD17B AKR1C3 is the predominant source of signaling androgens in HRPC.

PMID:
24771644
DOI:
10.1158/1078-0432.CCR-13-3483
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center